Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06138275 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Elranatamab in R/R Multiple Myeloma

Name: Elranatamab in R/R Multiple Myeloma — clinical trial record (NCT06138275)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorMassachusetts General Hospital

Started2024-03-08

View on ClinicalTrials.gov ↗

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.

Amendment history 1 change detected by DataLookout

2026-09-01

Primary completion pushed: 2026-08-01 → 2027-12-01

Trial Details

NCT Number	NCT06138275
Lead Sponsor	Massachusetts General Hospital Collaborators: Pfizer
Conditions	Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
Enrollment	32 participants
Start Date	2024-03-08
Primary Completion	2027-12-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-31